Echocardiographic Characterization of Cardiac Amyloidosis

Condition(s) studied

Study summary

This is a mono-center observational ambispective study in which patients with cardiac amyloidosis evaluated at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Rome, Italy) will be enrolled.

The primary aim is to investigate echocardiographic findings, particularly using advanced echocardiographic techniques, such as two- and three-dimensional speckle-tracking analysis, that may be helpful in the differential diagnosis between cardiac amyloidosis and other cardiomyopathies with hypertrophic phenotype.

Secondary aims are: 1) to evaluate the reversibility of myocardial damage, assessed by echocardiography, in response to a newly available specific treatment for patients with transthyretin-related cardiac amyloidosis (tafamidis) and its correlation with the clinical response 2) to investigate potential novel echocardiographic predictors of adverse cardiovascular outcomes.

Eligibility

Primary outcome measure(s)

• changes in echocardiographic parameters (in patients receiving or not specific treatment) — 6 months
  variation in global longitudinal strain, diastolic parameters and degree of ventricular hypertrophy
• cardiovascular outcomes — 24 months
  composite endpoint of death and heart failure hospitalization

Trial sites (1)

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

Other trials for the same condition